450,000 Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Purchased by Boxer Capital Management LLC

Boxer Capital Management LLC purchased a new stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 450,000 shares of the company's stock, valued at approximately $1,364,000. Boxer Capital Management LLC owned approximately 0.63% of Zentalis Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Prudential Financial Inc. acquired a new position in shares of Zentalis Pharmaceuticals during the 4th quarter worth approximately $39,000. Cerity Partners LLC acquired a new position in shares of Zentalis Pharmaceuticals in the fourth quarter worth $40,000. Ieq Capital LLC purchased a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter valued at $46,000. Oxford Asset Management LLP acquired a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter valued at $52,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Zentalis Pharmaceuticals during the 4th quarter worth about $53,000.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL stock traded down $0.02 during trading hours on Wednesday, reaching $1.24. The company had a trading volume of 364,082 shares, compared to its average volume of 1,543,765. The company has a market capitalization of $88.86 million, a P/E ratio of -0.50 and a beta of 1.81. Zentalis Pharmaceuticals, Inc. has a twelve month low of $1.01 and a twelve month high of $13.24. The stock's fifty day simple moving average is $1.54 and its 200 day simple moving average is $2.43.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its quarterly earnings data on Wednesday, March 26th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.09. The firm had revenue of $26.90 million during the quarter. As a group, equities analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on ZNTL. Wells Fargo & Company reduced their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating on the stock in a report on Thursday, January 30th. Wedbush restated a "neutral" rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, March 28th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a research note on Thursday, March 27th. Finally, UBS Group reduced their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $8.24.

Insider Buying and Selling

In other Zentalis Pharmaceuticals news, Director Scott Dunseth Myers bought 21,000 shares of the stock in a transaction dated Wednesday, April 30th. The stock was bought at an average cost of $1.40 per share, for a total transaction of $29,400.00. Following the completion of the purchase, the director now directly owns 281,192 shares of the company's stock, valued at approximately $393,668.80. The trade was a 8.07 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Ingmar Bruns purchased 20,000 shares of the business's stock in a transaction that occurred on Thursday, February 6th. The stock was acquired at an average price of $2.28 per share, for a total transaction of $45,600.00. Following the purchase, the insider now owns 36,629 shares of the company's stock, valued at approximately $83,514.12. This represents a 120.27 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by insiders.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.